Effectiveness of penfluridol (oral long acting neuroleptic) as compared to second generation oral neuroleptics in psychotic disorder patients: an open label randomized controlled trial - ZonMw

Abstract

Non-adherence with antipsychotics is common in patients with a psychotic disorder and is associated with more relapses and higher healtcare costs. Penfluridol is a first generation antipsychotic drug and currently the only long-acting oral agent that can be taken once a week. Second generation oral antipsychotic drugs such as olanzapine and risperidone have to be taken daily. In addition, penfluridol is also cheaper than oral second-generation antipsychotics mostly used today (including olanzapine and risperidone). Since this agent can be administered on a weekly basis, we expect that penfluridol will enhance patient adherence and therefore lower healthcare costs . This multi-center open label randomized controlled trial will provide an initial insight into the (cost-) effectiveness of this agent as compared to second generation antipsychotics, and whether the clinical guidelines could be updated.

Journal

Title: Impact

Abbreviated Title: impact

Publisher: Science Impact, Ltd.

ISSN (Print): 2398-7073

Publication date Created: August 08 2017

Publication date (Print): August 08 2017

Volume: 2017

Issue: 6

Pages: 22-24

Article

DOI: 10.21820/23987073.2017.6.22

Copyright statement: © 2017

License:

This work is licensed under a Creative Commons Attribution 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Product

Self URI (article page): http://www.ingentaconnect.com/content/10.21820/23987073.2017.6.22